Fresenius SE & Co. KGaA (FRA:FRE)
Germany · Delayed Price · Currency is EUR | Market Cap | 21.65B -9.1% |
| Revenue (ttm) | 22.99B +3.0% |
| Net Income | 1.47B +248.3% |
| EPS | 2.61 +248.3% |
| Shares Out | n/a |
| PE Ratio | 14.73 |
| Forward PE | 10.53 |
| Dividend | 1.05 (2.69%) |
| Ex-Dividend Date | May 25, 2026 |
| Volume | 433,015 |
| Open | 38.56 |
| Previous Close | 38.44 |
| Day's Range | 37.69 - 38.56 |
| 52-Week Range | 37.79 - 52.84 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 6, 2026 |
About Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. It also provides biosimilar drugs; enteral and parenteral nutrition prod... [Read more]
Financial Performance
In 2025, Fresenius SE & Co. KGaA's revenue was 22.87 billion, an increase of 4.19% compared to the previous year's 21.95 billion. Earnings were 1.26 billion, an increase of 168.37%.
Financial StatementsNews
EQS-DD: Fresenius SE & Co. KGaA: Michael Sen, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 08.05.2026 / 14:26 CET/CEST The issuer is solely responsi...
Fresenius Misses Q1 Estimates As China Pressure Hits Kabi
Fresenius Misses Q1 Estimates As China Pressure Hits Kabi
Fresenius SE & Co. KGaA Earnings Call Transcript: Q1 2026
Q1 2026 saw 5% organic revenue and 13% core EPS growth, with strong contributions from Kabi and Helios. Balance sheet strength improved, S&P upgraded the credit outlook, and full-year guidance was reconfirmed amid ongoing geopolitical and regulatory uncertainty.
Fresenius SE & Co. KGaA Slides: Q1 2026
Fresenius SE & Co. KGaA has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Fresenius SE & Co. KGaA Earnings release: Q1 2026
Fresenius SE & Co. KGaA released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Fresenius SE & Co. KGaA Quarterly report: Q1 2026
Fresenius SE & Co. KGaA has published its Q1 2026 quarterly earnings report on May 6, 2026.
Fresenius Q1 Net Income Rises; Reconfirms FY26 Guidance
(RTTNews) - Fresenius (FRE.DE) reported first quarter net income attributable to shareholders of Fresenius SE & Co. KGaA of 435 million euros compared to 229 million euros, last year. Earnings per ord...
Fresenius SE price target lowered to EUR 53 from EUR 57 at Citi
Citi lowered the firm’s price target on Fresenius SE (FSNUY) to EUR 53 from EUR 57 and keeps a Buy rating on the shares.
Fresenius SE price target lowered to EUR 56 from EUR 58 at Morgan Stanley
Morgan Stanley analyst Aisyah Noor lowered the firm’s price target on Fresenius SE (FSNUY) to EUR 56 from EUR 58 and keeps an Overweight rating on the shares. Published first…
Fresenius SE & Co. KGaA Slides: Credit presentation
Fresenius SE & Co. KGaA has posted slides in relation to its latest quarterly earnings report, which was published on April 8, 2026.
Fresenius SE price target raised to EUR 56.60 from EUR 53.60 at JPMorgan
JPMorgan raised the firm’s price target on Fresenius SE (FSNUY) to EUR 56.60 from EUR 53.60 and keeps an Overweight rating on the shares.
Fresenius SE price target raised to EUR 57 from EUR 56 at Deutsche Bank
Deutsche Bank analyst Falko Friedrichs raised the firm’s price target on Fresenius SE (FSNUY) to EUR 57 from EUR 56 and keeps a Buy rating on the shares. Published first…
Fresenius SE price target raised to EUR 58 from EUR 56 at Morgan Stanley
Morgan Stanley analyst Aisyah Noor raised the firm’s price target on Fresenius SE (FSNUY) to EUR 58 from EUR 56 and keeps an Overweight rating on the shares. Published first…
Fresenius SE & Co. KGaA Earnings Call Transcript: Q4 2025
Strong 2025 results with 7% organic revenue and 12% core EPS growth, robust cash flow, and a 5% dividend increase. 2026 guidance targets 4%-7% organic revenue growth and 5%-10% core EPS growth, with continued investment in innovation and digitalization.
Fresenius SE & Co. KGaA Shareholder letter: Q4 2025
Fresenius SE & Co. KGaA has published a letter to shareholders covering Q4 2025, which was released on February 25, 2026.
Fresenius SE & Co. KGaA Annual report: Q4 2025
Fresenius SE & Co. KGaA has published its Q4 2025 annual report on February 25, 2026.
Fresenius SE & Co. KGaA Annual report: Q4 2025
Fresenius SE & Co. KGaA has published its Q4 2025 annual report on February 25, 2026.
Fresenius SE & Co. KGaA Earnings release: Q4 2025
Fresenius SE & Co. KGaA released its Q4 2025 earnings on February 25, 2026, summarizing the period's financial results.
Fresenius SE & Co. KGaA Slides: Q4 2025
Fresenius SE & Co. KGaA has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 25, 2026.
Fresenius SE price target raised to EUR 57 from EUR 52 at Citi
Citi raised the firm’s price target on Fresenius SE (FSNUY) to EUR 57 from EUR 52 and keeps a Buy rating on the shares.
Fresenius SE price target lowered to EUR 56 from EUR 57 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Fresenius SE (FSNUY) to EUR 56 from EUR 57 and keeps an Overweight rating on the shares.
Fresenius SE & Co. KGaA Transcript: 44th Annual J.P. Morgan Healthcare Conference
Healthcare trends and portfolio transformation have positioned the company for growth, with strong performance in IV generics, nutrition, MedTech, and biopharma. Financial discipline and innovation drive double-digit EPS growth, while future plans focus on scaling core businesses and targeted capital deployment.
Fresenius SE & Co. KGaA Slides: Investor presentation
Fresenius SE & Co. KGaA has posted slides in relation to its latest quarterly earnings report, which was published on December 21, 2025.
Fresenius SE price target raised to EUR 57 from EUR 56 at Morgan Stanley
Morgan Stanley analyst Robert Davies raised the firm’s price target on Fresenius SE (FSNUY) to EUR 57 from EUR 56 and keeps an Overweight rating on the shares. Published first…
Fresenius SE & Co. KGaA Transcript: Status Update
Management outlined a bold strategy to double biopharma revenue and portfolio by 2030, targeting a 20% EBIT margin through innovation, cost leadership, and global commercial expansion. Strong financial performance, a robust pipeline, and significant investments in R&D and manufacturing underpin confidence in long-term growth and value creation.